Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals

Table 7 Indications excluded from selected analyses^a on the basis of disproportionately low disease prevalence among nonwhites

Drug	Indication
Ipilimumab	Melanoma
Vemurafenib	Melanoma
Taliglucerase alfa	Gaucher disease
Ivacaftor	Cystic fibrosis
Vismodegib	Basal cell carcinoma
Dabrafenib mesylate	Melanoma
Mipomersen sodium	Homozygous familial hypercholesterolemia
Trametinib dimethyl sulfoxide	Melanoma

ISSN: 1745-6215